RC
RLMD icon

RBF Capital’s Relmada Therapeutics RLMD Stock Holding History

RBF Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$835K Sell
120,000
-20,000
-14% -$94.6K 0.04% 313
2025
Q4 		$676K Sell
140,000
-23,261
-14% -$77.9K 0.03% 359
2025
Q3 		$328K Hold
163,261
– – 0.01% 453
2025
Q2 		$98K Hold
163,261
– – ﹤0.01% 575
2025
Q1 		$44.1K Hold
163,261
– – ﹤0.01% 566
2024
Q4 		$84.9K Sell
163,261
-2,213
-1% -$5.4K ﹤0.01% 531
2024
Q3 		$536K Hold
165,474
– – 0.03% 403
2024
Q2 		$496K Hold
165,474
– – 0.03% 380
2024
Q1 		$769K Hold
165,474
– – 0.04% 326
2023
Q4 		$685K Sell
165,474
-28,600
-15% -$84.7K 0.04% 327
2023
Q3 		$582K Hold
194,074
– – 0.04% 333
2023
Q2 		$477K Buy
+194,074
New +$537K 0.03% 369

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RBF Capital's RLMD Position: Q1 2026 in Review

RBF Capital reduced its Relmada Therapeutics (RLMD) stake by 14% in Q1 2026, selling an estimated $94.6K and leaving 120,000 shares worth $835K. The position accounts for 0.04% of the portfolio, ranked #313.

RBF Capital first reported a position in RLMD in Q2 2023 and has held it in 12 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • RBF Capital held 120,000 shares of Relmada Therapeutics worth $835K as of Q1 2026.
  • RBF Capital sold 20,000 Relmada Therapeutics shares in Q1 2026, an estimated $94.6K.
  • Relmada Therapeutics made up 0.04% of RBF Capital's portfolio in Q1 2026, its #313 holding.
  • RBF Capital first reported a position in Relmada Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on RBF Capital's 13F filing for Q1 2026, filed 15 May 2026.